BFC
EW icon

Bedel Financial Consulting’s Edwards Lifesciences EW Stock Holding History

Bedel Financial Consulting’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-300
Closed -$35K – 405
2022
Q1 		$35K Hold
300
– – 0.01% 458
2021
Q4 		$39K Hold
300
– – 0.01% 441
2021
Q3 		$34K Hold
300
– – 0.01% 444
2021
Q2 		$31K Buy
+300
New +$28.3K 0.01% 472
2020
Q2 		– Sell
-9
Closed -$1K – 832
2020
Q1 		$1K Buy
+9
New +$649 ﹤0.01% 735

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bedel Financial Consulting's EW Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Edwards Lifesciences (EW) in Q2 2022, closing a stake of 300 shares — an estimated $35K sold.

Bedel Financial Consulting first reported a position in EW in Q1 2020 and held it in 5 quarters. The position peaked at $39K in Q4 2021. 1,272 funds tracked by Wall St. Rank hold EW as of Q2 2022.

  • Bedel Financial Consulting reported no remaining Edwards Lifesciences position as of Q2 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 300 Edwards Lifesciences shares in Q2 2022, an estimated $35K.
  • Bedel Financial Consulting first reported a position in Edwards Lifesciences in Q1 2020 and held it in 5 quarters.
  • Bedel Financial Consulting's Edwards Lifesciences position peaked at $39K in Q4 2021.
  • 1,272 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.